Get the Stockscreener App
1.40
0.35%
-0.02
After Hours:
1.38
-0.02
-1.43%
Biomea Fusion Inc stock is traded at $1.40, with a volume of 1.34M.
It is down -0.35% in the last 24 hours and down -25.13% over the past month.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
See More
Previous Close:
$1.42
Open:
$1.44
24h Volume:
1.34M
Relative Volume:
0.91
Market Cap:
$101.22M
Revenue:
-
Net Income/Loss:
$-61.80M
P/E Ratio:
-0.9212
EPS:
-1.5197
Net Cash Flow:
$-70.37M
1W Performance:
+15.98%
1M Performance:
-25.13%
6M Performance:
+32.24%
1Y Performance:
-4.39%
1-Day Range:
$1.32
$1.445
1-Week Range:
$1.22
$1.464
52-Week Range:
$0.8719
$3.08
Biomea Fusion Inc Stock (BMEA) Company Profile
Name
Biomea Fusion Inc
Sector
Industry
Phone
(650) 980-9099
Address
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.40 | 102.67M | 0 | -61.80M | -70.37M | -1.5197 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Biomea Fusion Inc Stock (BMEA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Initiated | Rodman & Renshaw | Buy |
| Aug-28-25 | Initiated | Jefferies | Buy |
| Jun-03-25 | Resumed | Piper Sandler | Overweight |
| Oct-09-24 | Initiated | Edward Jones | Buy |
| Sep-27-24 | Upgrade | Rodman & Renshaw | Neutral → Buy |
| Sep-27-24 | Upgrade | Truist | Hold → Buy |
| Aug-29-24 | Initiated | CapitalOne | Overweight |
| Jun-11-24 | Downgrade | Truist | Buy → Hold |
| Jun-07-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-06-24 | Initiated | Truist | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Jun-26-23 | Downgrade | Jefferies | Buy → Hold |
| May-12-23 | Initiated | Barclays | Overweight |
| Mar-29-23 | Reiterated | Oppenheimer | Outperform |
| Mar-28-23 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-23 | Initiated | Citigroup | Buy |
| Jun-02-22 | Resumed | H.C. Wainwright | Buy |
| Jan-12-22 | Initiated | H.C. Wainwright | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| May-11-21 | Initiated | JP Morgan | Overweight |
| May-11-21 | Initiated | Jefferies | Buy |
| May-11-21 | Initiated | Piper Sandler | Overweight |
View All
Biomea Fusion Inc Stock (BMEA) Latest News
BMEA Stock Price, Quote & Chart | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
Biomea Fusion, Inc.Common Stock (NQ: BMEA - FinancialContent
Oppenheimer Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Raises Target Price to $7 - Moomoo
Biomea Fusion to Participate at Upcoming Investor Conferences - marketscreener.com
Analyst Reiterates Buy on Biomea Fusion, Maintains $4 Price Target Amid Advancing Metabolic Pipeline - TipRanks
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Biomea Fusion completes Icovamenib chronic tox studies and posts 52-week follow-up in diabetes pipeline - Traders Union
Biomea Fusion Inc (NASDAQ:BMEA) Q1 2026 Earnings Beat and Pipeline Progress Drive Cautious Optimism - ChartMill
Biomea Fusion Reports First Quarter 2026 Financial Results and Corporate Highlights - Investing News Network
BIOMEA FUSION ($BMEA) Releases Q1 2026 Earnings, Stock Rises - Quiver Quantitative
Biomea Fusion 4Q Loss/Shr 17c >BMEA - Moomoo
Biomea Fusion Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Biomea Fusion, Inc. Q1 2026: Net loss $(12.4)M, EPS $(0.17) — 10-Q Summary - TradingView
Biomea Fusion Q1 net loss narrows as expenses fall - TradingView
Biomea Fusion (BMEA) trims Q1 2026 loss but flags cash runway only into early 2027 - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biomea Fusion (Nasdaq: BMEA) cuts Q1 2026 loss while advancing diabetes and obesity pipeline - Stock Titan
Biomea diabetes drug shows 52% C-peptide boost at 12 weeks - Stock Titan
BMEA.O Technical Analysis & Stock Price Forecast - Intellectia AI
BMEA Technical Analysis | Trend, Signals & Chart Patterns | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
Icovamenib boosts C-peptide secretion in 52-week diabetes trial - Traders Union
This Applied Materials Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
Citizens Initiates Coverage of Biomea Fusion (BMEA) with Market Outperform Recommendation - MSN
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association (ADA) 86th Scientific Sessions - The Manila Times
Biomea Fusion to present new icovamenib data at American Diabetes Association event - Traders Union
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association 86th Scientific Sessions - Investing News Network
Biomea Fusion Announces Late-Breaking Poster Presentations on Icovamenib at ADA 86th Scientific Sessions - Quiver Quantitative
Three diabetes studies put Biomea's icovamenib in ADA late-breakers - Stock Titan
Biomea Fusion Announces Poster Presentations of Icovamenib at the American Diabetes Association ... - Caledonian Record
Biomea Fusion Announces Poster Presentations of Icovamenib - GlobeNewswire
Biomea Fusion Status Update: Experts Discuss Icovamenib’s Promise Ahead of ADA 2026 - Yahoo Finance
Citizens JMP Initiates Biomea Fusion(BMEA.US) With Buy Rating, Announces Target Price $9 - Moomoo
Citizens initiates Biomea Fusion stock coverage citing diabetes treatment potential By Investing.com - Investing.com South Africa
Citizens initiates Biomea Fusion stock coverage citing diabetes treatment potential - Investing.com Nigeria
Biomea Fusion Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
U.S. Earnings Preview: After Market Close May 1 - Moomoo
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
BMEA Should I Buy - Intellectia AI
BMEA Forecast, Price Target & Analyst Ratings | BIOMEA FUSION INC (NASDAQ:BMEA) - ChartMill
BMEA SEC FilingsBiomea Fusion, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Biomea Fusion Shares Early Type 1 Diabetes Data as COVALENT-112 Shows C-Peptide Gains with Icovamenib - MarketBeat
Biomea Fusion, Inc. (BMEA) Discusses Top Line Results From COVALENT-112 Trial of Icovamenib in Type 1 DiabetesSlideshow (NASDAQ:BMEA) 2026-04-28 - Seeking Alpha
Biomea Fusion (NASDAQ:BMEA) Given Buy Rating at D. Boral Capital - MarketBeat
Biomea Fusion Reports Positive Phase 2 T1D Trial Results - TipRanks
Biomea Fusion | 8-K: Current report - Moomoo
Phase 2 icovamenib T1D data from Biomea Fusion (NASDAQ: BMEA) show 52% C-peptide gain - Stock Titan
Biomea Fusion Is Maintained at Buy by D. Boral Capital - Moomoo
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment - markets.businessinsider.com
Biomea reports positive type 1 diabetes trial results By Investing.com - Investing.com Canada
Biomea reports positive type 1 diabetes trial results - Investing.com UK
Biomea Fusion Inc Stock (BMEA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):